MOL#101030 2 Structure of 7-methylcyanopindolol-bound β 1 AR
Introduction
The β 1 and β 2 adrenergic receptors (β 1 AR and β 2 AR) are well-studied prototypical members of the G protein-coupled receptor (GPCR) superfamily (Venkatakrishnan et al., 2013) . In vivo, the receptors are activated by both adrenaline and noradrenaline, with important clinical roles in modulation of cardiac output (β 1 AR) and bronchodilatation (β 2 AR). Recent successes in the structure determination of both β 1 AR (Warne et al., 2008; Moukhametzianov et al., 2011; Warne et al., 2011; Warne et al., 2012; Christopher et al., 2013; Miller-Gallacher et al., 2014) and β 2 AR Wacker et al., 2010; Rosenbaum et al., 2011; Rasmussen et al., 2011a; Rasmussen et al., 2011b) have led to a molecular understanding of receptor activation (Lebon et al., 2012) . Binding of a full agonist to the receptors results in a contraction of the ligand binding pocket by 1.0 Å for β 1 AR and 1.2 Å for β 2 AR and a rotamer change of Ser 5.46 so that it forms a hydrogen bond with the para-hydroxyl group of the catecholamine moiety of the agonist. However, the agonist-bound receptors remain in an overall conformation that is consistent with an inactive state.
The role of the agonist is thus to increase the probability of active state formation, but the agonist is insufficient on its own to stabilize the active state. A crystal structure of β 2 AR in the active state bound to the heterotrimeric G protein Gs (Rasmussen et al., 2011b) showed that the fully active state is characterized by the formation of a cleft in the intracellular face of the receptor and a 16 Å outward movement of the cytoplasmic end of transmembrane helix 6 (H6).
Structures have been determined of β 1 AR bound to full agonists , partial agonists , weak partial agonists (Warne et al., 2008; Moukhametzianov et al., 2011; Miller-Gallacher et al., 2014) and biased agonists . All these structures are in an inactive state, so the structures with This article has not been copyedited and formatted. The final version may differ from this version. agonists represent the encounter complex between the ligand and receptor before the receptor becomes activated. As mentioned above, full agonists cause a contraction of the binding pocket and cause a rotamer change of Ser 5.46 due to hydrogen bond formation. In addition, there is a rotamer change of Ser 5.42 . The combination of these changes results in the weakening of helix-helix interactions between H3, H4 and H5 that has been proposed to be the important initial event that increases the probability of the receptor adopting an active conformation . In support of this, partial agonists cause a contraction of the binding pocket, the rotamer change of Ser 5.42 , but not the rotamer change of Ser 5. 46 . Weak partial agonists cause only the rotamer change of Ser 5.42 , but not of Ser 5.46 and they do not cause the contraction of the ligand binding pocket due to the additional oxymethylene spacer in the backbone of the ligand (Fig 1) . Thus there appears to be a direct correlation between specific differences in the structure of the receptor-ligand complex and the efficacy of the ligand.
A prediction of the molecular mechanism for agonist activation of β 1 AR is that the efficacy of a ligand should be reduced upon the addition of a methyl group in the position analogous to the para-hydroxyl of, for example, isoprenaline , to prevent the rotamer change of Ser 5.46 by steric hindrance (see Fig. 1 for structures of ligands discussed in the text). To test this hypothesis, we therefore made the methylated version of cyanopindolol, 7-methylcyanopindolol. Cyanopindolol was used as the starting point for this study because its properties are pharmacologically and structurally well defined. Through the single modification of cyanopindolol to make 7-methylcyanopindolol, we could be certain that the only effect would be on the rotamer comformation of Ser 5. 46 . In this way we could be certain that any changes in efficacy were due to this modification and not any other differences in the ligand. 
Cell culture
Pharmacological studies were conducted in CHO cells stably expressing either the turkey β 1 AR (CHO-tβ1, receptor expression level 148 fmol/mg protein, defined as tβtrunc in (Baker, 2010b) or the human β 2 -adrenoceptor (CHO-hβ2, receptor expression level 466 fmol/mg protein; (Baker et al., 2003) ). Both of these cell lines also contained the stably transfected reporter gene CRE-SPAP. Negative control cells were parental CHO cells (CHO-CRE-SPAP cells), which are CHO cells with the stably transfected reporter but without any transfected receptor (Baker et al., 2003) .
Cells were grown in Dulbecco's modified Eagle's medium nutrient mix F12
(DMEM/F12) containing 10% foetal calf serum and 2 mM L-glutamine in a 37°C humidified 5% CO 2 : 95% air atmosphere. chromatography, as previously described (Baker, 2010b) . Basal activity and a positive control (response to 10 µM isoprenaline) were included in all plates for every experiment. Responses are therefore expressed as a percentage of this maximum, or in the case of inverse agonists, as a percentage of the basal response.
Data analysis
For whole cell binding, a sigmoidal binding curve (equation 1) was fitted to the concentration response curves using Graphpad Prism 2.01 and the IC 50 was then determined as the concentration required to inhibit 50% of the specific binding.
Equation 1: % uninhibited binding = 100 -(100 x A) + NS (A + IC 50 )
A is the concentration of the competing ligand, IC 50 is the concentration at which half of the specific binding of 3 H-CGP12177 has been inhibited, and NS is the nonspecific binding.
From this IC 50 value and the known concentration of 3 H-CGP12177, a K D value (concentration at which half the receptors are bound by the competing ligand) was calculated using equation 2. The K D values for 3 H-CGP12177 were 0.42 nM at the turkey β 1 AR (Baker, 2010b) and 0.17 nM at the human β 2 AR (Baker, 2010a) . are the respective EC 50 values for the two agonist sites.
All data are presented as the mean ± standard error of the mean (SEM) of n separate experiments. Step 1: Synthesis of 2-(benzyloxy)-5-methylbenzaldehyde. 2-Hydroxy-5methylbenzaldehyde (5.00 g, 36 mmol) was dissolved in DMF (30 ml), K 2 CO 3 (6.07 g, 44 mmol) and benzyl bromide (4.36 ml, 36 mmol) were added, the reaction mixture was warmed to 65°C and stirred for 6 h. The reaction mixture was cooled to room temperature and poured into water (500 ml). The precipitate was filtered, washed with water (100 ml) and dried to give 2-(benzyloxy)-5-methylbenzaldehyde (7.0 g, 84 % Step 2 Step 3: synthesis of 4-(benzyloxy)-7-methyl-1H-indole-2-carboxylic acid.
Synthesis of 4-[(2S)-3-(tert-butylamino
Methyl 4-(benzyloxy)-7-methyl-1H-indole-2-carboxylate (0.9 g, 3.0 mmol) was dissolved in ethanol (30 ml) and 2N NaOH was added (41.4 ml, 105 mmol), the reaction mixture was stirred for 4 h at 90°C. The reaction mixture was cooled to room temperature and acidified to pH 4 with aqueous 3N HCl. The precipitate was filtered, wash with water (100 ml) and dried to give 4-(benzyloxy)-7-methyl-1H-indole-2- Step 4: synthesis of 4-(benzyloxy)-7-methyl-1H-indole-2-carboxamide. 4-(benzyloxy)-7-methyl-1H-indole-2-carboxylic acid (0.9 g, 3.1 mmol) was dissolved in diethyl ether (18 ml). Thionyl chloride (0.78 g, 6.5 mmol) was added at 0°C and the reaction mixture stirred at room temperature for 5 h. The solvents were removed in vacuo and the residues were dissolved in diethyl ether (10 mL). The reaction mixture was cooled to -20°C and ammonia gas was bubbled through for 5 min. The solvents were removed in vacuo and the crude product was purified by column chromatography (normal phase silica, 10 to 20% ethyl acetate in hexane) to give 4-(benzyloxy)-7-methyl-1H-indole-2-carboxamide (0.6 g, 67% yield) as a white solid. Step 5: synthesis of 4-hydroxy-7-methyl-1H-indole-2-carboxamide. 4-(Benzyloxy)-7-methyl-1H-indole-2-carboxamide (0.6 g, 2.4 mmol) was dissolved in methanol (20 ml) and 10% Pd/C (0.2 g, 1.8 mmol) was added. The reaction mixture was stirred at room temperature under 1 atm of H 2 gas for 8 h. The reaction mixture was filter through celite and the solvents were removed in vacuo to give 4-hydroxy-7- Step 6: synthesis of 4-hydroxy-7-methyl-1H-indole-2-carbonitrile. 4-Hydroxy-7-methyl-1H-indole-2-carboxamide (0.4 g, 2.1 mmol) was dissolved in 1,4dioxane (4 ml). POCl 3 (0.5 ml) was added and the reaction mixture was stirred at 75°C
LCMS (Method
for 15 min. The reaction mixture was cooled to room temperature partitioned and quenched with ammonia solution (5 mL), partitioned between H 2 O (50 ml) and
EtOAc (100 ml Step 7 Step 8 45, 29.25, 45.63, 50.17, 69.38, 71.22, 101.62, 104.73, 111.47, 114.42, 115.24, 117.72, 126.70, 138.40, 151.32 .
Expression, purification, and crystallization of β 1 AR. The β44-TS construct was used, which contained additional thermostabilising mutations, I129 3.40 V, E130 3.41 W, Y343 7.53 L (Miller and Tate, 2011) to the previously published turkey (Meleagris gallopavo) β 1 AR construct, β44-m23 (Warne et al., 2009; Warne et al., 2011) . The construct used here is identical to that used for the structure determination of β 1 AR at 2.1 Å resolution (Miller-Gallacher et al., 2014) , except that it contains the E130 3.41 W mutation to improve the amount of functional receptor expressed and Asp322 is identical to the wild type receptor, instead of being mutated to Lys to form a salt bridge in the extracellular region. None of these mutations affect the structure of the binding pocket of the receptor. Ballesteros-Weinstein numbers are shown as superscripts (Ballesteros, 1995) . Expression of β44-TS using recombinant baculovirus and receptor purification were all performed as described previously (Warne et al., 2003; Warne et al., 2009 ), although expression was performed in High Five TM cells grown in ESF921 medium (Expression systems). A 2-fold increase in functional expression to 8 mg/L culture was observed with this construct compared with β44-m23, which is most likely attributable to the inclusion of the mutation E130 3.41 W (Roth et al., 2008) .
Solubilisation of the receptor from the membrane fraction was performed using 1 and concentrated down again to 0.1 ml. This step was repeated twice and finally receptor was concentrated to 30 -50 mg/ml. Before crystallization, CHS was added from a concentrated stock (10 mg/ml in 2% DM) to give a final concentration of 2 mg/ml CHS and 0.4% DM. Protein determination was performed using the amido black assay (Schaffner and Weissmann, 1973 (Leslie, 2006) and AIMLESS (Evans, 2006; Evans, 2011 (Murshudov et al., 1997; Murshudov et al., 2011) , COOT (Emsley et al., 2010) and MOLPROBITY (Davis et al., 2007; Chen et al., 2010) .
Results
The affinity of 7-methylcyanopindolol for turkey β 1 AR and human β 2 AR 7-Methylcyanopindolol was synthesized in an 8-step process to yield 20 mg of pure product as defined by LCMS and the structure was confirmed by 1 H and 13 C NMR (see Methods). The affinity of 7-methylcyanopindolol for turkey β 1 AR and human β 2 AR was compared with other well-characterized antagonists through competition binding assays using 3 H-CGP12177 and performed on whole cells ( Fig. 3 and Table   I ). The affinity of turkey β 1 AR for 7-methylcyanopindolol was 43 ± 3 pM (n=6), which is very similar to its affinity for cyanopindolol (35 ± 3 pM, n=6). Human β 2 AR This article has not been copyedited and formatted. The final version may differ from this version. bound both ligands with similar affinities to turkey β 1 AR. The affinities of the receptors for two other antagonists (used in the efficacy studies below), carazolol and ICI118551, were also determined and were found to be similar to previous determinations (Baker, 2010a; Baker, 2010b) .
The efficacy of 7-methylcyanopindolol at turkey β 1 AR Previous studies have shown a large response window in 3 H-cAMP accumulation measurements in a CHO cell line stably expressing turkey β 1 AR (CHO-tβ 1, 148 fmol of receptor per mg protein) to measure small responses in ligand efficacy (Baker, 2010a) . Isoprenaline stimulated an increase in 3 H-cAMP accumulation that was 22.5 ± 1.3 fold over basal, confirming a large response window (n=4; Fig. 4 ). As previously observed (Baker, 2010b) , cyanopindolol elicited a biphasic response curve with the maximum response reaching 31.8 ± 1.1% (n=4) of the response elicited by the full agonist isoprenaline (Table II) . In contrast, 7-methylcyanopindolol gave a response that reached a maximum of 2.3 ± 0.3% (n=4) of that attained by isoprenaline. Whilst it appeared that this response was best described by a single site sigmoidal response curve, a second component cannot be excluded because the increase in 3 H-cAMP was so small. ICI118551, a potent inverse agonist of β 2 AR (Bond et al., 1995; Azzi et al., 2001) , gave no response. Carazolol was previously described as a partial inverse agonist of the human β 2 AR although other studies have shown it to stimulate a partial agonist response at the human β 1 AR and β 2 AR (Baker, 2010a) and the turkey β 1 AR . Here, carazolol was again shown to be a weak partial agonist of turkey β 1 AR, and it elicited a biphasic response similar to that seen for cyanopindolol ( Fig. 4 and Table II ), and similar to that seen at the human β 1 AR (Baker, 2010a) . The efficacy of 7-methylcyanopindolol at human β 2 AR
The results from the previous section indicated that 7-methylcyanopindolol was an exceedingly weak partial agonist of turkey β 1 AR, but as no convincing inverse agonism was detected in this assay with ICI118551, the experiments were repeated on human β 2 AR (cell line CHO-hβ2, receptor expression level 466 fmol receptor per mg protein), which has higher basal activity than β 1 AR (Engelhardt et al., 2001) .
Isoprenaline stimulated a large increase in 3 H-cAMP accumulation in CHO-β2 cells (61.4 ± 5.4 (n=8) fold over basal; Fig. 4 ). Cyanopindolol was found to stimulate an agonist response (with a maximum stimulation of 8.0 % that of isoprenaline, Figure 4 , Table III ) and a small stimulation was also seen in response to carazolol. When 7methyl-cyanopindolol was examined, there was no increase in 3 H-cAMP accumulation, but rather a very small decrease in basal activity. As inverse agonism has previously been reported in this cell line (Baker et al., 2003) , the response to 7methylcyanopindolol was examined alongside that of the known inverse agonist ICI118551 (Fig. 4 ). ICI118551 was confirmed to have inverse agonist activity resulting in a decrease of basal activity by 55%. The inverse activity of 7-methylcyanopindolol was found to be less, causing a decrease in basal activity by 25%.
Efficacy of 7-methylcyanopindolol in CRE-gene transcription responses
The β-antagonist propranolol acts as an inverse agonist of the G protein-coupled pathway, causing a decrease in cAMP production, but it stimulates CRE-gene transcription in the CHO-hβ2 cell line through signaling via the G proteinindependent MAP kinase pathway through β-arrestins (Baker et al., 2003) . As 7methylcyanopindolol was found to be a weak inverse agonist, its response at the level of CRE-gene transcription was also investigated. For turkey β 1 AR, the CRE-gene transcription responses observed for cyanopindolol was similar to the response in the 3 H-cAMP accumulation studies (Fig. 5 , Table II ), but no response was detected for 7methylcyanopindolol. For human β 2 AR, an agonist response was observed for cyanopindolol, but 7-methylcyanopindolol did not stimulate an increase in CRE-SPAP production ( Figure 5 , Table III ). There is thus no evidence for biased signaling through β-arrestins by 7-methylcyanopindolol.
Negative control experiments in CHO-CRE-SPAP cells (i.e. with no transfected receptor) showed that 10 µM forskolin stimulated a response that was 18.3 ± 4.7 fold over basal (n=4) in the 3 H-cAMP accumulation assay (not shown) and 5.9 ± 0.5 fold over basal (n=4) in the CRE-gene transcription assays. No response was observed in CHO-CRE-SPAP cells upon addition of either cyanopindolol, 7-methylcyanopindolol, carazolol or isoprenaline (n=4 in each case; Figure 5 ).
Structure of 7-methylcyanopindolol-bound β 1 AR
To produce high-quality crystals of β 1 AR, a thermostabilized version of the receptor was used that contained 9 thermostabilizing mutations in addition to truncations at the N-terminus, C-terminus and cytoplasmic loop 3 (see Materials and Methods). Thermostabilized β 1 AR was expressed using the baculovirus expression system, purified by Ni 2+ -affinity chromatography and alprenolol sepharose affinity chromatography (Warne et al., 2003; Warne et al., 2009 ) and crystallized using the lipidic cubic phase technique (Miller-Gallacher et al., 2014) . Data were collected at synchrotron microfocus beamlines and the structure determined by molecular replacement and refined to a final resolution of 2.4 Å (Table IV ). The final model contained one receptor molecule per asymmetric unit, associated with 2 Na + ions, 5
This article has not been copyedited and formatted. The final version may differ from this version. lipids and 28 water molecules, with good density for 7-methylcyanopindolol in the ligand binding pocket (Fig. 6 ). The receptor is in the inactive state and is virtually identical to the structure of cyanopindolol-bound receptor (PDB code 4BVN; RMSD 0.19 Å over 2062 atoms) (Miller-Gallacher et al., 2014) . The major difference in the ligand binding pocket between β 1 AR bound to either cyanopindolol or 7methylcyanopindolol is that the hydroxyl group of Ser215 5.46 is displaced 0.8 Å from its position when cyanopindolol is bound, in a direction away from the center of the receptor.
Discussion
The synthesis of 7-methylcyanopindolol has allowed further understanding of the components that affect ligand efficacy in β 1 AR. Previous data suggested that the rotamer change of Ser215 5.46 and a contraction of the ligand binding pocket were sufficient to increase the probability of formation of the activated state of the receptor Warne and Tate, 2013) . Therefore ligands that prevented rotamer changes of Ser215 5.46 and prevented contraction of the orthosteric binding pocket should, in theory, have greatly reduced efficacy and may even become inverse agonists. Cyanopindolol was described previously as a weak partial agonist of both human and turkey β 1 AR (Baker, 2010a; Baker, 2010b ) and so we therefore synthesized 7-methylcyanopindolol, with the methyl group in a position predicted to dramatically decrease its efficacy. Pharmacological analysis of 7methylcyanopindolol showed that it bound with similar high affinity to both turkey β 1 AR and human β 2 AR, and that there was a marked reduction in efficacy at both receptors. However, at the turkey β 1 AR, 7-methylcyanopindol was an exceedingly weak partial agonist whereas for β 2 AR the ligand acted as a weak partial inverse agonist. Thus the goal was achieved in reducing efficacy, but raised the question of why a tiny amount of agonist activity could still be detected at β 1 AR, whereas ICI118551 did not elicit any response.
In efforts to further understand the molecular mechanism of 7methylcyanopindolol, the structure of 7-methylcyanopindolol-bound β 1 AR was determined at 2.4 Å resolution, which is sufficient to determine unambiguously the rotamer conformation and precise positioning of serine side chains. Comparison of this structure with structures of β 1 AR bound either to cyanopindolol (Miller-Gallacher et al., 2014) or carazolol , both weak partial agonists, showed that the binding pocket was actually slightly larger than expected by 0.3-0.5 Å, as measured between the Cα atoms of Ser211 5.42 and Asn329 7.39 . In addition, there was a difference in position of the hydroxyl group of Ser215 5.46 in the 7methylcyanopindolol-bound structure compared to the cyanopindolol-bound structure of 0.8 Å, in a direction away from the ligand, presumably due to the proximity of the methyl group of 7-methyl cyanopindolol. Both the increase in size of the binding pocket and the outward shift of the hydroxyl group of Ser215 5.46 are consistent with the dramatic reduction in efficacy of 7-methylcyanopindolol compared to cyanopindolol. If an analogous comparison is performed in the structures of β 2 AR bound to the weak partial agonist carazolol and the inverse agonist ICI118551 (Wacker et al., 2010) , exactly the same differences are observed, i.e. an expansion of the binding pocket of 0.4 Å (measured as above) and a 0.7 Å shift of the hydroxyl group of Ser207 5.46 (Fig. 7) .
Although Ser215 5.46 appears to be a major determinant in defining ligand efficacy, two other serine residues have also been implicated by mutagenesis in the activation of β-receptors, namely Ser211 5.42 and Ser212 5.43 (Strader et al., 1989 ;
This article has not been copyedited and formatted. The final version may differ from this version. Liapakis et al., 2000) . The orientation of Ser211 5.42 has been suggested to correlate with decreased efficacy of ligands, based on the comparison of β 1 AR structures bound to 8 different ligands . Structures of β 1 AR bound to agonists and partial agonists, including β 1 AR bound to cyanopindolol and 7methylcyanopindol, invariably have the side chain of Ser211 5.42 in a gauche + rotamer, whereas β 1 AR bound to carazolol and carvedilol have Ser211 5.42 in a trans rotamer (see Fig. 7A ). Thus one possibility to explain the residual agonist activity of 7methylcyanopindolol is that the slight destabilization of the H5 interface between H3 and H4 caused by the gauche + orientation of the Ser211 5.42 side chain is sufficient to make the ligand an extremely weak partial agonist. The role of Ser212 5.43 in determining ligand efficacy is less clear, as it does not make direct contact to the ligand, but instead forms a hydrogen bond with Asn310 6.55 that may assist in orienting the side chain for optimal hydrogen bond formation with full agonists . As Asn310 6.55 forms van der Waals contacts with the weak partial agonists studied here, as opposed to a hydrogen bond with full agonists, then its effect may be minimal in determining the efficacy of the weak partial agonists given that different rotamers of Asn310 6.55 would presumably always be in weak van der Waals contact with the ligand. This view is supported by the absence of the Ser212 5.43 -Asn310 6.55 hydrogen bond in one structure of cyanopindolol-bound β 1 AR (Miller-Gallacher et al., 2014) , although it is clearly present in other cyanopindolol-bound structures (Warne et al., 2008) .
In considering the factors that dictate the efficacy of a ligand for β 1 AR, there appears to be a hierarchy of factors that have a diminishing effect as you go down the list. Firstly, the most important factor is probably the contraction of the binding pocket upon agonist binding, which has been observed in all structures bound to full or partial agonists . Without this contraction, it is unlikely that hydrogen bonds would be able to form between the catecholamine moiety of the agonist and the side chains of Ser215 5.46 and Ser211 5.42 . Secondly, the rotamer change of Ser215 5.46 is important as this dictates the difference in binding between a full and partial agonist, and allows hydrogen bond formation to the ligand . Thirdly, the rotamer change of Ser211 5.42 , in addition to its defining role in the binding of partial agonists, may promote lower levels of activity in antagonists when the binding pocket is less likely to contract and Ser215 5.46 is less likely to rotate due to steric clashes with the ligand . Currently, we do not know where in this hierarchy the importance of Ser212 5.43 falls. Mutagenesis suggests that this is an important residue in determining agonist affinity in β 2 AR (Strader et al., 1989 ) and in the structures of β 1 AR it usually forms a hydrogen bond with Asn310, that in turn forms a strong hydrogen bond to the catecholamine headgroup (or equivalent) when agonists bind to the receptor . As it appears that the hydrogen bond is present in the activated state of the β 2 AR bound to the G protein mimic Nb80 (Rasmussen et al., 2011a) , it seems likely that ligands which reduce the probability of this bond forming will have poor efficacy, although no such ligands have been described so far.
In conclusion, we have demonstrated that a single modification of cyanopindolol to make 7-methylcyanopindolol was sufficient to reduce dramatically the efficacy of the ligand and the structure of the ligand-receptor complex has confirmed the importance of the rotamer conformation of Ser215 5.46 in receptor activation and inverse agonist activity. The unexpected residual agonist activity of the ligand highlights the role of Ser211 5.42 in ligand-induced activation of β 1 AR and that it This article has not been copyedited and formatted. The final version may differ from this version. is not just playing a passive role in increasing ligand affinity. Further work will therefore be needed to finally make a high-affinity inverse agonist for β 1 AR.
Coordinates and structure factors for 7-methylcyanopindolol-bound β 1 AR have been deposited with the Protein Data Bank, PDB ID 5A8E.
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